Enhertu recommended for approval in the EU by CHMP for patients with previously treated HER2-positive metastatic solid tumours May 26, 2026
FDA Accepts Supplemental BLA for ANKTIVA + BCG in BCG-Unresponsive NMIBC with Papillary Disease; PDUFA Jan 2027 May 26, 2026
First patients dosed with [212Pb]VMT-α-NET and [212Pb]PSV359 in two new cohorts of Ph 1/2a studies in neuroendocrine tumors and solid tumors May 26, 2026
Liminatus Pharma Announces Proposed Merger with InnocsAI to Expand Oncology Cell Therapy Pipeline May 26, 2026
Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload May 26, 2026
First patient dosed in Spain in Ph 2 HLX43-NSCLC201 trial of HLX43 for the treatment of advanced NSCLC May 26, 2026
Ph 3 Trial of Sacituzumab Tirumotecan (sac-TMT) vs Chemo as 1L Treatment for Advanced TNBC Met Primary Endpoint of PFS May 26, 2026
HREC Australia approves HLX3902 for Clinical Trial in Australia in metastatic CRPC and other advanced solid tumours May 26, 2026
Camizestrant in combination with a CDK4/6 inhibitor recommended for approval in the EU by CHMP for 1L advanced ER+ve breast cancer May 26, 2026
Successful Outcome of FDA Type C Meeting Request for HARMONIC Ph 2 Trial of LP-300 in Never-Smokers with NSCLC Announced May 26, 2026
Positive EU CHMP Opinion for KEYTRUDA + Padcev as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable MIBC May 26, 2026
Datroway approved in the US in 1L metastatic TNBC patients not PD-1/PD-L1 inhibitor candidates May 26, 2026
